Showing results (481-490 of 538) with videos related to

Sort By:
Pageof 54
The Oncologist|June 15, 2023
Neoadjuvant Talazoparib in Patients With Germline BRCA1/2 Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II StudyJennifer K Litton, J Thaddeus Beck, Jason M Jones, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 4, 2010
Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabineJavier Cortes, Linda Vahdat, Joanne L Blum, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2015
Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of CapecitabineJoyce O'Shaughnessy, Hartmut Koeppen, Yuanyuan Xiao, et al.
Archives of Women'S Mental Health|September 17, 2025
Effects of a Personalized Stress Management Intervention on Maternal Mental Health: A Randomized Clinical TrialS Darius Tandon, Judith T Moskowitz, Renee C Edwards, et al.
The Oncologist|March 13, 2020
Talazoparib in Patients with a Germline BRCA-Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA TrialSara A Hurvitz, Anthony Gonçalves, Hope S Rugo, et al.
The British Journal of Dermatology|August 25, 2018
Dermatological manifestations in cardiofaciocutaneous syndrome: a prospective multicentric study of 45 mutation-positive patientsD Bessis, F Morice-Picard, E Bourrat, et al.
Lancet (London, England)|March 8, 2011
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised studyJavier Cortes, Joyce O'Shaughnessy, David Loesch, et al.
Clinical Breast Cancer|December 17, 2008
The effect of tamoxifen or exemestane on bone mineral density during the first 2 years of adjuvant treatment of postmenopausal women with early breast cancerStephen Jones, Christopher Stokoe, Mark Sborov, et al.
Cancer Medicine|April 22, 2026
Impact of Comorbidities on Clinical Outcomes and Quality of Life of Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Advanced Breast Cancer Treated With Palbociclib in the POLARIS StudyDebu Tripathy, Joanne L Blum, Meghan S Karuturi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2022
Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast CancerJoanne L Blum, A Douglas Laird, Jennifer K Litton, et al.
Pageof 54